APR 02, 2018 06:37 PM PDT

Treating Rare Pediatric Cancers

WRITTEN BY: Nouran Amin

Research published in The Lancet Oncology explains how the drug Larotrectinib can treat cancer cells that have a specific fusion of two genes. Larotrectinib received FDA designation and can treat any cancer type with a fusion gene. "In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it's not supposed to be and that causes the cells to grow uncontrollably. What's unique about the drug is it is very selective; it only blocks TRK receptors," said lead investigator Dr. Ted Laetsch, a Professor of Pediatrics at Harold C. Simmons Comprehensive Cancer Center.

Larotrectinib is part of a group molecules designated as ‘kinase inhibitors’ which work to cut back on the enzyme actions of cellular mechanisms. In this case, Larotrectinib targets TRK fusions which are present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors. Some TRK fusions occur in only a small percentage of common adult cancers however the rest are more commonly seen in rare pediatric cancers including infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer. "Every patient with a TRK fusion-positive solid tumor treated on this study had their tumor shrink. The nearly universal response rate seen with larotrectinib is unprecedented," explains Dr. Laetsch.

One child treated with Larotrectinib was 13-year-old aspiring fashion designer Briana Ayala of El Paso. Briana had a rare tumor located in her abdomen and wrapped around her aorta, which made it risky for surgical operation. So, Briana and her family were there encouraged to visit Children’s Health in Dallas, TX where she underwent a specialized operation that removed only portions of her aorta and most of the tumor. Unfortunately, this did not treat Briana’s cancer as it began to return. With no treatments available, Dr. Laetsch sent Briana’s tumor for genetic testing where it was analyzed to have a TRK fusion making it possible to be treated by Larotrectinib

After Briana’s enrollment in phase 1 clinical trial of the new drug, results have shown that swelling in her abdomen has been diminished along with a shrunken tumor. "These are the kind of amazing responses we've seen with larotrectinib," said Dr. Laetsch, "and this is why I'm so excited about it."

What’s particularly unique about larotrectinib is it doesn’t lead to severe side effects like most other cancer therapeutics and for many patients the response was long-lasting. "For some of the targeted drugs in the past, many patients responded initially, but then resistance developed quickly. To date, the response to this drug seems to be durable in most patients," said Dr. Laetsch.

Sources: The Lancet Oncology, Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Potential Targeted Treatment for Crohn Disease
Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract. Now,...
NOV 12, 2018
Cancer
NOV 12, 2018
Targeted radiation therapy may provide new hope to children with difficult-to-treat liver cancer
Primary malignant liver tumors are rare in children with an occurrence rate of 1-2% of all childhood cancers. Radical surgical resection of the liver which means the removal of part of the li...
NOV 25, 2018
Drug Discovery
NOV 25, 2018
'Longevity protein' Improves Healing in Aging Muscles
A downside to aging is that the skeletal muscles lose their ability to heal after muscle injury. However, a recent research study at the University of Pitt...
DEC 26, 2018
Drug Discovery
DEC 26, 2018
Novel Water Approach May Improve Drug Design
An understanding of the basic molecular properties of water greatly influences drug design. But, a significant comprehension of water interactions and its ...
JAN 01, 2019
Drug Discovery
JAN 01, 2019
Restoring The Fountain of Youth
According to a study published in Nature Communications, a drug treatment that aided the immune system in eradicating old cells in aging mice assisted in t...
JAN 11, 2019
Drug Discovery
JAN 11, 2019
Histamine Improves Long-Term Memory
A recent research study found that histamine could improve people’s long-term memory which may be a prospective treatment option to alleviate symptom...
Loading Comments...